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Abstract
Background: Component-resolved diagnostics (CRD) are promising tools for diag-
nosing food allergy, offering the potential to determine specific phenotypes and to
develop patient-tailored risk profiles. Nevertheless, the diagnostic accuracy of these
tests varies across studies; thus, their clinical utility remains unclear. Therefore, we
synthesized the evidence from studies investigating the diagnostic accuracy, risk
assessment ability, and cost-effectiveness of CRD for food allergy.
Methods: We systematically searched 10 electronic databases and four clinical trial
registries for studies published from January 2000 to February 2017. The quality of
included studies was assessed using QUADAS-2. Due to heterogeneity, we narra-
tively synthesized the evidence.
Results: Eleven studies met inclusion criteria, altogether recruiting 1098 partici-
pants. The food allergies investigated were cow’s milk, hen’s egg, peanut, hazelnut,
and shrimp. The components with the highest diagnostic accuracy for each allergen,
along with their sensitivity-specificity pairs, were as follows: Bos d 4 for cow’s milk
(62.0% and 87.5%), Gal d 1 for hen’s egg (84.2% and 89.8% for heated egg, and
60.6% and 97.1% for raw egg), Ara h 6 for peanut (94.9% and 95.1%), Cor a 14 for
hazelnut (100% and 93.8%), and Lit v 1 for shrimp (82.8% and 56.3%) allergy.
Conclusion: Selected components of cow’s milk, hen’s egg, peanut, hazelnut, and
shrimp allergen showed high specificity, but lower sensitivity. However, few studies
exist for each component, and studies vary widely regarding the cutoff values used,
making it challenging to synthesize findings across studies. Further research is
needed to determine clinically appropriate cutoff values, risk assessment abilities,
and cost-effectiveness of CRD approaches.
K E YWORD S
component-resolved diagnostics, cost-effectiveness, diagnostic test accuracy systematic review,
food allergy, risk assessment
Abbreviations: aa, amino acid; APT, atopy patch test; CRD, component-resolved diagnostics; DBPCFC, double-blind, placebo-controlled food challenge; DTA, diagnostic test accuracy;
HSROC, hierarchical summary receiver operating characteristic; IgE, immunoglobulin E; NPV, negative predictive value; PPV, positive predictive value; QUADAS-2, quality assessment of
diagnostic accuracy studies-2; ROB, risk of bias; ROC, receiver operating characteristic; sIgE, specific immunoglobulin E; SPT, skin prick test.
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1 | INTRODUCTION
The high prevalence of food allergy is now an emerging global public
health concern.1 Estimates of the prevalence of food allergy vary,
but overall lifetime prevalence has been estimated to be between
4% and 7% for children and between 3% and 6% for adults in eco-
nomically developed countries.2,3 The quality of life of patients with
food allergy is often severely affected, resulting in considerable mor-
bidity and healthcare utilization, including risk of accidental exposure
leading to life-threatening anaphylactic reactions.4
An accurate diagnosis of food allergy is essential to provide
appropriate, potentially life-saving advice on how to prevent and
manage allergic reactions and prevent unnecessary dietary restric-
tions.1,4 The diagnosis of food allergy is dependent on a thorough
clinical history as well as an objective marker of allergic sensitization
and, in some cases, oral food challenge tests.5 Current first-line tests
to assess allergen sensitization are skin prick tests (SPT) and/or
immunoassays of serum food-specific IgE (sIgE) levels. However,
these approaches have a high rate of false-positive results and are
poor predictors of the severity of allergic reactions.4 Thus, diagnostic
confirmation with (ideally) a double-blinded placebo-controlled food
challenge (DBPCFC) is often required.5 While DBPCFCs are consid-
ered the gold standard diagnostic tests, they are costly, technically
challenging, time-consuming, labor-intensive, and are associated with
important safety risks, as they can trigger anaphylactic reactions.4
Given the limitations of conventional methods for diagnosing
food allergy, new molecular-based diagnostic techniques—collec-
tively referred to as component-resolved diagnostics (CRD)—have
emerged as promising diagnostic tools.6 While current approaches
evaluate patients’ reactivity to whole food extracts, CRD involves
detecting sIgE levels to individual allergenic molecules or the epi-
topes of those allergens.7 This approach may enhance determination
of specific food allergy phenotypes, assist in the development of
patient-tailored risk profiles for specific food allergens, and improve
detection of possible cases of cross-reactivity between different
allergenic molecules.8
Over the last decade, researchers have compared CRD to con-
ventional diagnostic approaches for food allergy.9 Through this work,
the major allergen components in different food allergies have been
identified. However, the diagnostic accuracy of identified compo-
nents varies across studies, and thus, the diagnostic value and clinical
utility of CRD remains unclear.9,10 CRD approaches are also expen-
sive, which raises questions about their cost-effectiveness.11
While the diagnostic accuracy of various tests for food allergy
was evaluated in our previous systematic review, CRD was not
included.12 A health technology assessment was carried out to evalu-
ate multiplex CRD assays, but clinical effectiveness (rather than diag-
nostic accuracy) was investigated.13 To the best of our knowledge,
only one CRD-specific diagnostic test accuracy (DTA) review has
been conducted, but it focused solely on peanut allergy diagnosis.14
This review concluded that Ara h 2 showed superior diagnostic accu-
racy than SPT and sIgE tests, and therefore has the potential to
replace first-line tests for the diagnosis of peanut allergy. Given the
increasing body of work, there is a need to undertake a more com-
prehensive evidence synthesis on the diagnostic accuracy of CRD.
We therefore conducted a systematic review to: (i) determine the
accuracy of CRD for the diagnosis of food allergy, focusing on the
“big eight” food allergies (ie, cow’s milk, wheat, hen’s egg, peanut,
soy, tree nuts, fish, and shellfish allergy); (ii) estimate the effective-
ness and cost-effectiveness of CRD in comparison with conventional
techniques for the diagnosis of these food allergies; and (iii) summa-
rize the evidence on the ability of CRD to predict the severity of
allergic reactions. We focused on these eight food allergies to align
with the foods considered in our previous systematic reviews for the
European Academy of Allergy and Clinical Immunology.2,12
2 | METHODS
The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist guided the reporting of this systematic
review (see Table S1).15 Our protocol was published16 and preregis-
tered (PROSPERO:CRD42016053512).
2.1 | Eligibility criteria
We included prospective, retrospective, cross-sectional, and case-con-
trol studies that examined the accuracy of CRD in diagnosing cow’s
milk, hen’s egg, wheat, soybean, peanut, tree nuts, fish, or shellfish
allergy in children or adults. Studies were required to have sufficient
data to calculate the following four relevant diagnostic measures: sen-
sitivity, specificity, positive predicted value (PPV), and negative predic-
tive value (NPV). Additionally, all studies were required to have a
defined study population with either consecutive or random sampling
of participants. Studies in which the recruitment technique used to
select participants was not indicated were included, and the lack of
information regarding their sampling methodology was noted during
the quality assessment process. The reference standard was DBPCFC
used in at least 50% of the participants.
2.2 | Search strategy
Although CRD methods were originally described in the 1990s,17
their application to food allergy diagnosis was not clinically imple-
mented until the 2000s.1 Hence, we chose the beginning of 2000 as
the starting time for the literature search. We searched the following
databases from January 2000 to February 2017: AMED (Ovid), CAB
Abstracts (Ovid), the Cochrane Library, CINAHL (EBSCO), EMBASE
(Ovid), Global Health (Ovid), PsycINFO (Ovid), Web of Science Core
Collection (Thomson Reuters), WHO’s Global Health Library and the
Health Economic Evaluations Database. Our full search strategy is
included in the online supplement (Table S2). We also contacted
international experts who have published in the field, screened the
references cited in identified studies, and used the citation-tracking
feature of Google Scholar to find any additional studies. The list of
contacted experts can be found in the online supplement (Table S3).
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Additionally, the International Standard Randomized Controlled Trial
Number (ISRCTN) Registry, ClinicalTrials.gov, the Australian and New
Zealand Clinical Trials Registry, and WHO’s International Clinical Tri-
als Registry Platform (ICTRP) were searched to identify relevant
ongoing studies. No language restrictions were applied.
2.3 | Study selection and data collection
Two reviewers (JFK and NM) independently screened titles and
abstracts and then reviewed full-texts to identify eligible studies.
Authors of studies for which further details were required to deter-
mine inclusion or exclusion were contacted to obtain further infor-
mation to enable a decision. For papers in languages other than
English, speakers of the language in question were contacted to
determine eligibility. Both reviewers independently extracted data
from included studies using a form developed specifically for this
systematic review. Study characteristics, DTA measures (ie, sensitiv-
ity, specificity, PPV and NPV), and 2 9 2 contingency tables (reflect-
ing the number of true positives, true negatives, false positives, and
false negatives) were extracted. DTA measures and 95% confidence
intervals were calculated from 2 9 2 contingency tables when not
provided by authors.18-20 The two reviewers assessed the quality of
the included studies using the Quality Assessment of Diagnostic
Accuracy Studies-2 (QUADAS-2) tool.21 Discrepancies were resolved
by discussion and consensus, or when necessary, arbitrated by a
third reviewer (BN).
2.4 | Data synthesis, analysis, and reporting
Diagnostic accuracy measures (sensitivity, specificity, PPV, and NPV)
of individual studies were summarized in tables and presented by
allergy type and individual allergen component. We had planned to
conduct meta-analyses of the evidence with respect to each allergen
component by fitting a bivariate model (when included studies used
a common threshold) or a hierarchical summary receiver operating
characteristic (HSROC) model (when included studies used multiple
thresholds). However, we were unable to do this, as the number of
studies for each component was too small to permit quantitative
syntheses. In a simulated analysis based on the Bayesian approach, it
was recommended that a minimum of four studies were required to
reasonably fit these models.22 In a very few cases, we had a maxi-
mum of three studies per allergen component; the most common
was two studies. The statistical programs we tried to use to fit the
models (R and Stata) indicated that the models lacked convergence,
as a result of containing too few studies. For these reasons, we nar-
ratively synthesized the evidence.
3 | RESULTS
3.1 | Study selection
A total of 10 380 articles were identified through the literature
search carried out on June 15, 2016. After excluding duplicate
articles, 6853 titles and abstracts were screened against the inclu-
sion and exclusion criteria; of these, 195 full-text papers were
assessed. Thirteen articles reporting 11 studies met our criteria and
were thus included.23-35 Additionally, one potentially relevant ongo-
ing clinical trial was found in ClinicalTrials.gov (details can be found
in Table S4). The literature search was updated on February 9, 2017,
to incorporate newly published papers. No additional relevant stud-
ies were identified in the updated search. The study screening and
selection processes are summarized in Figure 1. A list of potentially
relevant studies can be found in the Online supplement (Tables S5
and S6). The authors of these studies did not reply to a request for
further information.
3.2 | Characteristics of included studies
Table 1 summarizes the main characteristics of the 11 studies
included. The studies altogether recruited a total of 1098 participants.
Nine studies were carried out in Western Europe,23-28,30,32,33 and
two multicenter studies analyzed data from multiple countries.31,34
Two studies used a case-control design,32,34 while nine were cross-
sectional studies.23-28,30,31,33 Two of the cross-sectional studies used
consecutive sampling to recruit participants,26,28 while the sampling
strategy used in the remaining seven cross-sectional studies was
unclear.23-25,27,30,31,33 Taking all studies together, 87% of participants
underwent DBPCFC to verify their food allergy status.
The included studies analyzed the diagnostic accuracy of CRD
for the following types of food allergy: cow’s milk (n = 2),23,33 hen’s
egg (n = 3),24,25,33 peanut (n = 3),28,30,31 hazelnut (n = 2),27,32 and
shrimp (n = 2).26,34 No studies investigated the other allergies of
interest (i.e, wheat, soybean, and fish). All but one study analyzed a
single type of allergy; this study analyzed the diagnostic accuracy of
CRD for both cow’s milk and hen’s egg.33 Five studies used the
ImmunoCAP test to measure sIgE levels,23,25-27,31,32 three studies
used microarray techniques (ISAC CRD 51, ISAC 103, and ISAC
112),24,28,33 one study used a combination of ImmunoCAP and a
microarray technique (ISAC 112),30 and one study used an
immunoblotting technique for sIgE detection.34 Two studies addi-
tionally analyzed the DTA of individual component epitopes using
immunoblotting techniques.26,34
3.3 | Quality assessment of included studies
Table 1 includes a summary of the QUADAS-2 quality assessment
for each study. Table S7 in the supplementary information provides
the detailed QUADAS-2 assessments.
3.3.1 | Patient selection
Two studies were rated as high risk of bias (ROB) in this domain because
of the use of a case-control design.32,34 Eight other studies were found
to have an unclear ROB, mainly because they did not explicitly indicate
their sampling methodology and/or did not avoid inappropriate exclu-
sions.23-25,27,28,30,31,33 The remaining study had a low ROB.26
FLORES KIM ET AL. | 1611
3.3.2 | Index test
Two studies had high ROB in this domain because they did not use
prespecified thresholds for determining positive results.27,33 Eight
studies had unclear ROB because they did not report whether index
test results were interpreted without knowledge of DBPCFC
results.23-26,28,31,32,34 Only one study had low ROB in this domain.30
Two studies used immunoblotting assays to analyze sIgE reactivity
against allergens; because these assays do not provide quantitative
sIgE levels, these two studies were scored as unsure in terms of
their applicability to this review’s research question.26,34
3.3.3 | Reference standard
One study did not specify the criteria used to classify DBPCFC results
and was thus scored as having an unclear ROB in this domain.26 Two
F IGURE 1 PRISMA Diagram for the literature search
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studies were scored as unsure in terms of their applicability to this
review’s research question.30,32 The reason for this appraisal was that
the purpose of this review was to assess the accuracy of CRD and its
ability to predict allergy severity (both of which are assessed through
objective symptoms in a DBPCFC), and the two aforementioned stud-
ies included patients with mild or subjective DBPCFC symptoms in the
same group as patients with negative DBPCFC.
3.3.4 | Patient flow and timing
Two studies had a high ROB in this domain because less than 100%
of patients underwent DBPCFCs, and not all patient data were
included in their data analysis.26,34 Three studies specified the time
interval between index and reference tests, compared all patients
against the same reference standard, included all patients in data
analysis, and were thus ranked as low ROB in this domain.24,25,27
The remaining six studies failed to meet at least one of those criteria
and were thus scored as having an unclear ROB.23,28,30-33
3.4 | Diagnostic accuracy of CRD
DTA measures for all the 11 studies are presented in Table 2. The
information in this table includes data points for all sIgE cutoff val-
ues that the included studies used to define test positivity, as some
studies used multiple values. In the following narrative synthesis, we
present the results of the diagnostic accuracy of all components per
food allergy type for only cutoff values with the highest diagnostic
potential as defined in each study.
3.4.1 | Cow’s milk allergy
Two studies evaluated CRD for cow’s milk allergy,23,33 and the fol-
lowing components were assessed: Bos d 4 (a-lactalbumin), Bos d 5
(b-lactoglobulin), Bos d 8 (caseins), and the caseins (a-, b-, and j-)
separately. The reported sensitivity-specificity for these components
were as follows: for Bos d 4, 62.0% and 87.5% (with a cutoff value
defining a positive test of >0.01 kUa/L),23 and 50.0% and 93.0% (at
>0.1 FI)33; for Bos d 5, 82.0% and 62.5% (at >0.35 kUa/L),23 and
23.8% and 95.3% (at >0.1 FI)33; for Bos d 8, 88.0% and 56.3% (at
>0.35 kUa/L)23; and the casein with the highest DTA was j-casein
with a sensitivity-specificity pair of 38.1% and 88.4% (at >0.1 FI).33
3.4.2 | Hen’s egg allergy
Three studies evaluated CRD for hen’s egg allergy,24,25,33 and the fol-
lowing components were assessed: Gal d 1 (ovomucoid), Gal d 2 (oval-
bumin), Gal d 3 (ovotransferrin), and Gal d 4 (lysozyme). Two studies
investigated heated egg and raw egg allergy separately,24,25 while the
third study analyzed only raw egg allergy.33 For heated egg allergy, the
reported sensitivity-specificity for these components were as follows:
for Gal d 1, 84.2% and 89.8% (at >0.01 kUa/L),24 and 76.3% and
81.4% (at >4.4 kUa/L)25; for Gal d 2, 52.6% and 83.7% (at >0.01 kUa/
L),24 and 73.7% and 72.9% (at >6.33 kUa/L);25 and for Gal d 3, 21.1%
and 93.9% (at >0.01 kUa/L).24 For raw egg allergy, the reported sensi-
tivity-specificity for these components were as follow: for Gal d 1,
60.6% and 97.1% (at >0.01 kUa/L),24 73.1% and 82.9% (at >2.26 kUa/
L),25 and 57.8% and 86.7% (at >0 FI)33; for Gal d 2, 42.4% and 88.6%
(at >0.01 kUa/L),24 and 76.1% and 82.9% (at >3.88 kUa/L),25 and
57.8% and 80.0% (at >0 FI)33; for Gal d 3, 18.2% and 97.1% (at
>0.01 kUa/L)24; and for Gal d 4, 17.8% and 100% (at >0 FI).33
3.4.3 | Peanut allergy
Three studies evaluated the diagnostic accuracy of CRD for peanut
allergy,28,30,31 and the following components were assessed: Ara h 1
(cupin, a 7S globulin), Ara h 2 (conglutin, a 2S albumin), Ara 3 (cupin,
a 11S globulin), Ara h 6 (conglutin, a 2S albumin), Ara h 8 (Bet v 1
homologue), and Ara h 9 (LTP). The reported sensitivity-specificity
for these components were as follows: for Ara h 1, 56.6% and
86.9% (at >0.35 kUa/L),31 and 60.7% and 95.1% (at >0.8 kUa/L)30;
for Ara h 2, 69.2% and 90.5% (at >0.3 ISU/L),28 80.2% and 91.8%
(at >0.35 kUa/L),31 and 80.3% and 95.1% (at >1.8 kUa/L)30; for Ara
h 3, 48.1% and 90.2% (at >0.35 kUa/L),31 and 55.7% and 95.1% (at
>0.8 kUa/L)30; for Ara h 6, 61.5% and 95.2% (at >1.0 ISU/L)28, and
94.9% and 95.1% (at >0.8 ISU)30; for Ara h 8, 34.9% and 42.6% (at
>0.35 kUa/L),31 and 78.7% and 14.6% (at >0.35 kUa/L)30; and for
Ara h 9, 14.8% and 85.4% (at >0.35 kUa/L).30
3.4.4 | Hazelnut allergy
Two studies evaluated the diagnostic accuracy of CRD for hazelnut
allergy,27,32 and the following components were assessed: Cor a 1
(PR-10 protein), Cor a 8 (LTP), Cor a 9 (11S seed storage globulin),
and Cor a 14 (2S albumin). Additionally, one of the studies investi-
gated whether sensitization to the allergens Bet v 1 (PR-10 protein)
and Bet v 2 (profilin) (from the European White Birch) could also
predict hazelnut allergy.32 The reported sensitivity-specificity for
these components were as follows: for Cor a 1, 79.7% and 7.3% (at
>0.35 kUa/L32; for Cor a 8, 6.3% and 96.3% (at >0.35 kUa/L)32; for
Cor a 9, 100% and 71.9% (at >0.65 kUa/L),27 and 54.4% and 97.6%
(at >1 kUa/L)32; for Cor a 14, 100% and 93.8% (at >0.64 kUa/L),27
and 54.4% and 85.4% (at >0.35 kUa/L)32; for Bet v 1, 81.0% and
7.3% (at 0.35 kUa/L)32; and for Bet v 2, 10.1% and 81.7% (at
0.35 kUa/L).32
3.4.5 | Shrimp allergy
Two studies reported data on CRD for shrimp allergy.26,34 One study
tested the component Pen a 1 (tropomyosin) using the ImmunoCAP
test,26 and the other study investigated the components Lit v 1 (tro-
pomyosin) and Lit v 4 (sarcoplasmic calcium-binding protein) through
an immunoblotting technique.34 Additionally, both studies investi-
gated the diagnostic value of several individual epitopes in shrimp
through an immunoblotting technique. The components (and their
epitopes) tested in this manner were as follows: Lit v 1, Lit v 2 (argi-
nine kinase), Lit v 3 (myosin light chain), and Lit v 4. The reported
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sensitivity-specificity pair of Lit v 1 was 82.8% and 56.3%, and of Lit
v 4 was 34.5% and 93.8%,34 and the reported sensitivity-specificity
pair of Pen a 1 was 88.2% and 23.8% (at >0.35 kUa/L).26 With
regards to epitope data, the epitopes with highest DTA were found
on Lit v 1 and Lit v 2.26,34 Table S8 in the online supplement pre-
sents the full DTA data by epitope.
3.5 | Cost-effectiveness of CRD
None of the studies meeting our inclusion criteria evaluated the
cost-effectiveness of CRD or made mention of any economic consid-
erations. The only relevant evidence identified was two manufac-
turer-authored abstracts featuring Markov simulation-based cost-
utility models for CRD vs DBPCFC for peanut allergy and one with
unspecified methodology featuring multiple food allergies; contacting
the authors confirmed there were no accompanying peer-reviewed
papers.36-38
3.6 | Risk assessment ability of CRD
Two studies assessing CRD for hen’s egg allergy found that sIgE levels
for all components tested were higher in patients with more severe
allergies.24,25 Another study found similar results for cow’s milk-aller-
gic patients.23 For peanut allergy, one study found that patients with
more severe food challenge reactions had higher sIgE levels to Ara h 1,
2, 3, and 6 than did patients with no reaction or mild symptoms.30 Fur-
thermore, this study found that all severe allergic patients were sensi-
tized to Ara h 2 or Ara h 6, and none of them were sensitized to Ara h
1, 3, or 9 without Ara h 2.30 For hazelnut allergy, one study found that
higher sIgE levels to Cor a 9 and Cor a 14 were associated with more
severe reactions in food challenges, but found no correlation between
sIgE levels to Cor a 1 or Cor a 8 and reaction severity.32
4 | DISCUSSION
4.1 | Summary of key findings
This systematic review included 11 studies that assessed the accuracy
of CRD in diagnosing cow’s milk, hen’s egg, peanut, hazelnut, and
shrimp allergies. Overall, the components tested by the studies
included in this review were as follows: Bos d 4, Bos d 5, Bos d 8, and
the caseins for cow’s milk allergy; Gal d 1, Gal d 2, Gal d 3, and Gal d 4
for hen’s egg allergy; Ara h 1, Ara h 2, Ara 3, Ara h 6, Ara h 8, and Ara
h 9 for peanut allergy; Cor a 1, Cor a 8, Cor a 9, Cor a 14, Bet v 1, and
Bet v 2 for hazelnut allergy; and Pen a 1, Lit v 1, and Lit v 4 for shrimp
allergy. No studies meeting our inclusion criteria investigated CRD for
diagnosing wheat, soy, and fish allergies. The components with the
highest diagnostic accuracy reported, along with their sensitivity-spe-
cificity pairs, were as follows: Bos d 4 for cow’s milk allergy (62.0%
and 87.5%), 23 Gal d 1 for hen’s egg allergy (84.2% and 89.8% for
heated egg, and 60.6% and 97.1% for raw egg),24 Ara h 6 for peanut
allergy (94.9% and 95.1%),30 Cor a 14 for hazelnut allergy (100% and
93.8%),27 and Lit v 1 for shrimp (82.8% and 56.3%).34 Additionally,T
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two studies found that individual epitopes in shrimp’s Lit v 1 and Lit v
2 could potentially have high diagnostic accuracy measures.26,34
Of the included studies, one study had a high ROB score in two
of the four QUADAS-2 domains,34 and four studies had one such
score.26,27,32,33 The remaining six studies were scored low or unclear
ROB in all four domains.23-25,28,30,31
4.2 | Strengths and limitations
To the best of our knowledge, this is the first systematic review ana-
lyzing the evidence on the diagnostic accuracy of CRD for a range
of food allergies. The strengths of this study include the use of a
highly sensitive search strategy with no language restrictions, which
allowed a comprehensive literature search, conducted across several
databases and clinical trial registries. The inclusion criteria for this
review were carefully selected to provide clinically relevant informa-
tion.16 Similar work in the field, including a RAND report and a system-
atic review by the European Academy of Allergy and Clinical
Immunology (EAACI) Food Allergy and Anaphylaxis Guidelines
Group,12,39 was used as bases for the inclusion criteria of this review.
Furthermore, the internal validity of the studies included in this review
was strong, as they all used DBPCFC as the reference standard in at
least 50% of participants. A limitation of this review is that due to the
large degree of heterogeneity between studies that met the inclusion
criteria (in terms of the components tested, the particular CRD assay
employed, and the cutoff values used), a quantitative synthesis of data
could not be undertaken. Additionally, we acknowledge that food
allergies other than the ones we focused on are becoming increasingly
important. As our search strategy was broadly formulated, we were, in
response to expert peer-review feedback, able to check for any other
potentially relevant studies for other foods. We were however unable
to find any such studies. In the future, in the context of planned
updates to this review, we plan to formally include terms for other
foods (eg, apple, cherry, and peach) as this may impact on the sensitiv-
ity of our searches.
4.3 | Comparison of findings with the wider
literature
The results of this review corroborate the findings of a previous
DTA systematic review on CRD for peanut allergy,14 suggesting that
sIgE levels to the component Ara h 2 can provide diagnostic mea-
sures with very high accuracy. Our review, however, used more rig-
orous inclusion criteria than the previous one, strengthening the
DTA evidence in relation to this component. The studies included in
our review that analyzed peanut components also found that sIgE
levels to the components Ara h 1, 3, 8, and 9 showed varying
results, most with underperforming diagnostic values.14 Neverthe-
less, this is the first review to present evidence on the diagnostic
value of Ara h 6 as a CRD component, which was found to have
higher sensitivity and specificity values than Ara h 2.
When comparing the diagnostic accuracy of CRD found in our
review with that of first-line diagnostic tests for food allergy (atopy
patch tests (APT), SPT, and sIgE) reported in a previous systematic
review,12 results vary by allergy. For cow’s milk allergy, Bos d 4 and
Bos d 8 have similar DTA results to APT and sIgE (these tests
showed sensitivity-specificity pairs of 52.8% and 88.1%, and 87.3%
and 47.7%, respectively); additionally, these components displayed
lower sensitivity and higher specificity than SPT (which showed a
sensitivity-specificity pair of 87.9% and 67.5%).12 For hen’s egg
allergy, Gal d 1 had lower sensitivity and higher specificity than SPT
and sIgE (these tests showed sensitivity-specificity pairs of 92.4%
and 58.1%, and 93.4% and 49.2%, respectively) for both raw and
heated egg.12 For peanut allergy, Ara h 6 showed higher DTA mea-
sures than SPT and sIgE (these tests showed sensitivity-specificity
pairs of 94.7% and 61.0%, and 96.3% and 59.3%, respectively).12
Although the previous systematic review did not carry out meta-ana-
lysis for hazelnut and shrimp allergies, results from individual studies
suggest that Cor a 9 and Cor a 14 may have higher DTA measures
than SPT and sIgE for hazelnut allergy and that Lit v 1 shows mar-
ginally lower sensitivity and higher sensitivity than SPT and sIgE.12
4.4 | Implications for research
We have identified important research gaps in this field. First, there
is a limited body of methodologically robust evidence to assess the
accuracy of CRD in diagnosing food allergies. From potentially rele-
vant studies identified through database searches, 21 were excluded
because they did not carry out DBPCFC in at least 50% of partici-
pants, and 27 were excluded because their food challenges were not
double-blind placebo-controlled. Furthermore, we did not identify
any methodologically strong studies assessing the diagnostic accu-
racy of CRD for wheat, soy, or fish allergies. Therefore, there is a
need for more DTA studies using DBPCFC as the reference standard
in >50% of participants to better assess the diagnostic accuracy of
CRD for food allergies. Alternatively, because of the challenges that
DBPCFC pose for researchers and patients, there is a need to sys-
tematically assess whether other types of diagnoses, such as a com-
bination of open food challenges and other markers of sensitization
as recently proposed,40 could be used as a reference standard for
DTA studies.
Second, this review found that at present, a quantitative synthesis
of CRD diagnostic accuracy data is not possible because of the paucity
of studies for each of the components that have been studied. Given
that CRD is still in development, there is a need for more studies and a
consensus reached on the optimal cutoff values that will facilitate
quantitative evidence synthesis and data pooling across studies. Alter-
natively, the heterogeneity of cutoff values could be alleviated if all
DTA studies reported appendices with sIgE concentration values for
each participant. This would allow reviewers to obtain DTA summary
measures from all studies in a transparent and homogenous manner.
Third, there is a need to standardize all CRD assays to ensure
that results are comparable between different tests. This includes
the individual allergen components used, the results obtained from
assays from different manufacturers, and the results obtained from
microarray and single-component tests.
FLORES KIM ET AL. | 1619
Finally, there is a dearth of evidence on the cost-effectiveness
and the risk assessment ability of CRD relative to current care mod-
els. In principle, it may be possible to utilize some of the data
obtained here for use in economic modeling to facilitate comparisons
of the relative value of any trade-off between sensitivity and speci-
ficity in a more formal manner. Such analyses were beyond the
scope of this review.
4.5 | Implications for patient care
Selected CRD components have the potential to diagnose food aller-
gies with a higher specificity, but lower sensitivity than current first-
line tests. Furthermore, risk assessments carried out by five of the
included studies suggest that quantitative measurements of sIgE
levels to key components have the potential to identify patients with
more severe allergic phenotypes. Such is the case for Ara h 2 and
Ara h 6 for peanut allergy, and Cor a 9 and Cor a 14 for hazelnut
allergy. Nevertheless, further research is necessary to draw stronger
conclusions and to determine the components with the highest diag-
nostic value, as well as the clinically appropriate cutoff values.
Importantly, all studies included in this review recruited patients
with suspected allergies. Therefore, it is likely that the prevalence of
allergies in the study populations is considerably higher than in more
population-based settings, rendering the tests’ PPVs higher and NPVs
lower than they would be in populations with lower allergy preva-
lence.
5 | CONCLUSIONS
The findings of this review suggest that some CRD components
have the potential to diagnose cow’s milk, hen’s egg, peanut, hazel-
nut, and shrimp allergies with high specificity, but low sensitivity.
Nevertheless, at present, there is not enough methodologically
robust evidence to draw definite conclusions. Further studies
employing DBPCFC as the reference standard are urgently needed
to effectively evaluate the DTA and cost-effectiveness of CRD, as
well as standardization of the components assessed and CRD assays
used, and consensus on study reporting.
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